SUVEN PHARMACEUTICALS: TO PRESENT MASUPIRDINE PHASE-3
**SUVEN PHARMACEUTICALS: TO PRESENT MASUPIRDINE PHASE-3 AND TENACLIDINE PHASE-1 DATA AT CTAD 2026** SUVEN - **Masupirdine – Phase 3:** To present baseline demographics and clinical characteristics from its global Phase 3 study evaluating…



















